Abbott Laboratories (ABT) — Stock Price, Financials & Analysis

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company offers pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices. The company was formerly known as Abbott Alkaloidal Company and changed its name to Abbott Laboratories in 1915. Abbott Laboratories was founded in 1888 and is based in Abbott Park, Illinois.

Key Statistics — ABT

  • Latest Close: $109.72
  • Market Cap: $189.86B
  • P/E Ratio (TTM): 35.6
  • EPS (TTM): $3.08
  • Dividend Yield: 232.00%
  • Beta: 0.58
  • 52-Week High: $137.49
  • 52-Week Low: $81.97
  • Profit Margin: 11.6%
  • Return on Equity: 10.6%
  • Debt to Equity: 63.2

Sector: Healthcare — Medical Devices

Income Statement — ABT

  • 2021: Revenue N/A, Net Income N/A
  • 2022: Revenue $43.65B, Net Income $6.93B
  • 2023: Revenue $40.11B, Net Income $5.72B
  • 2024: Revenue $41.95B, Net Income $13.40B
“”Wednesday, August 12, 2026
Minimaxmax⁡x∈Δmin⁡y∈Δ x⊤ ⁣A y=v∗\max_{x \in \Delta} \min_{y \in \Delta} \, x^\top\! A \, y = v^*maxx∈Δ​miny∈Δ​x⊤Ay=v∗§Zero-Sum∑i=1nui(s)=0    ∀ s∈S\textstyle\sum_{i=1}^{n} u_i(s) = 0 \;\; \forall \, s \in S∑i=1n​ui​(s)=0∀s∈S§Nash Eq.x∗⊤ ⁣Ay≥x∗⊤ ⁣Ay∗≥x⊤ ⁣Ay∗x^{*\top}\! A y \geq x^{*\top}\! A y^* \geq x^\top\! A y^*x∗⊤Ay≥x∗⊤Ay∗≥x⊤Ay∗§ExpectedE[u1]=x⊤ ⁣A y\mathbb{E}[u_1] = x^\top\! A \, yE[u1​]=x⊤Ay§RegretRT=max⁡i∑t=1Tuit−∑t=1TuattR_T = \max_i \sum_{t=1}^{T} u_i^t - \sum_{t=1}^{T} u_{a_t}^tRT​=maxi​∑t=1T​uit​−∑t=1T​uat​t​§LP Dualmin⁡y,ww    s.t.    Ay≤w⋅1\min_{y,w} w \;\; \text{s.t.} \;\; Ay \leq w \cdot \mathbf{1}miny,w​ws.t.Ay≤w⋅1§Payoffu1(i,j)=aij,    u2(i,j)=−aiju_1(i,j) = a_{ij}, \;\; u_2(i,j) = -a_{ij}u1​(i,j)=aij​,u2​(i,j)=−aij​§Minimaxmax⁡x∈Δmin⁡y∈Δ x⊤ ⁣A y=v∗\max_{x \in \Delta} \min_{y \in \Delta} \, x^\top\! A \, y = v^*maxx∈Δ​miny∈Δ​x⊤Ay=v∗§Zero-Sum∑i=1nui(s)=0    ∀ s∈S\textstyle\sum_{i=1}^{n} u_i(s) = 0 \;\; \forall \, s \in S∑i=1n​ui​(s)=0∀s∈S§Nash Eq.x∗⊤ ⁣Ay≥x∗⊤ ⁣Ay∗≥x⊤ ⁣Ay∗x^{*\top}\! A y \geq x^{*\top}\! A y^* \geq x^\top\! A y^*x∗⊤Ay≥x∗⊤Ay∗≥x⊤Ay∗§ExpectedE[u1]=x⊤ ⁣A y\mathbb{E}[u_1] = x^\top\! A \, yE[u1​]=x⊤Ay
0∑×$0 sometimesAlpha v0.1.0

The Shounya

HomeScreenerHeatmapSectorsDividendsCompareWatchlistPortfolioChartTechnicalScannerEarningsCorrelationSector AnalysisInsidersCongressNewsLearnAboutStatus
← Home← ScreenerChart TerminalTechnical
ABTHealthcare

Abbott Laboratories — Healthcare · Medical Devices

$109.72+1.10 (+1.01%)
Mkt Cap
$189.86B
P/E
35.6
EPS
$3.08
Beta
0.58
Yield
232.00%
52W Hi
$137.49
52W Lo
$81.97
Vol
12.5M

Price History

Chart Terminal →Technical Analysis →

Company Profile

Sector
Healthcare
Industry
Medical Devices
Employees
122,000
HQ
Abbott Park, IL, United States
Web
abbott.com

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company offers pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices. The company was formerly known as Abbott Alkaloidal Company and changed its name to Abbott Laboratories in 1915. Abbott Laboratories was founded in 1888 and is based in Abbott Park, Illinois.

Top Executives

NameTitleTotal Pay
Mr. Robert B. FordExecutive Chairman & CEO$4.4M
Mr. Philip P. BoudreauCFO & Executive VP of Finance$2.1M
Mr. Daniel Gesua Sive SalvadoriExecutive VP and Group President of Established Pharmaceuticals & Nutritional Products$1.5M
Mr. Christopher J. ScogginsExecutive Vice President of Diabetes Care$2.1M
Ms. Lisa D. EarnhardtExecutive VP & Group President of Medical Devices$2.4M
Ms. Sabina EwingSenior VP of Business & Technology Services and Chief Information Officer—
Mr. Michael ComillaVice President of Investor Relations.—
Erica L. BattagliaVP and Chief Ethics & Compliance Officer—
Ms. Elizabeth C. CushmanExecutive VP, General Counsel & Secretary—
Ms. Melissa BrotzSenior Vice President of Global Marketing & External Affairs—

Financial Statements

✓
Profitable
4/5 periods
✓
Revenue Growing
+5.7% latest, 2/3 up
✗
Earnings Growing
-51.3% latest, 1/3 up
✗
Pays Dividend
No dividends
✓
Positive Margin
11.6% net margin

Abbott Laboratories

Healthcare \u00b7 Medical Devices

Market Cap$189.86B
Trailing P/E35.6
Forward P/E18.1
EPS (trailing)$3.08
EPS (forward)$6.06
Gross Margin56.8%
Operating Margin14.7%
Profit Margin11.6%
Dividend Rate$2.52/share
Dividend Yield232.0%
Payout Ratio79.0%

Revenue & Net Income

2021 – 2025, Annual

Revenue

Net Income

Profit Margins

2021 – 2025, Annual

Earnings Per Share

2021 – 2025, Annual

Dividends

No dividend history available.

Price Ranges

52-Week
$81.97$137.49
Fwd P/E18.1
Avg Volume12.5M
Shares Out1.73B

Key Ratios

Gross Margin56.8%
Operating Margin14.7%
Profit Margin11.6%
ROE10.6%
ROA5.3%
P/B3.7
D/E63.21
Current Ratio1.38
Dividend Rate$2.52
Payout Ratio79.0%

Cash & Debt

Cash 15%Debt 85%
Total Cash$5.60B
Total Debt$32.72B
Net Cash$-27.12B
Free Cash Flow$7.21B
Operating CF$9.91B

Ratings Snapshot

2.5 / 5
P/E2/5(35.6)
P/B3/5(3.7)
ROE3/5(10.6)
ROA3/5(5.3)
D/E1/5(63.2)
Liquidity3/5(1.4)

Growth Pulse

Revenue Growth+13.0%
Earnings Growth-47.5%

Analyst Recommendations

0m
Buy (27 analysts)
4
16
7
Strong Buy: 4
Buy: 16
Hold: 7
Sell: 0
Strong Sell: 0
MonthStr BuyBuyHoldSellStr Sell
0m416700
-1m416700
-2m417700
-3m416700

Income Snapshot 2025

Revenue
$44.3B
Net Income
$6.5B
Gross Margin
56.4%
Net Margin
14.7%
Op. Income
$8.1B
EPS
$3.76

Balance Sheet

2021 – 2025, Annual
Debt / Equity0.27x
Owns more than it owes — healthy
Current Ratio1.58x
Can easily cover short-term bills
Net Debt$5.34B
Total debt minus cash on hand

Assets vs Liabilities vs Equity

Assets = Liabilities + Equity. The green bar is what's left for shareholders after paying all debts.

Cash vs Debt

How much cash the company has on hand vs how much it owes in total debt.

Period Detail

PeriodAssetsLiabilitiesEquityCashDebtD/E
2021N/AN/AN/AN/AN/A—
2022$74.44B$37.53B$36.69B$9.88B$17.72B0.48x
2023$73.21B$34.39B$38.60B$6.90B$15.63B0.40x
2024$81.41B$33.51B$47.66B$7.62B$15.02B0.32x
2025$86.71B$33.94B$52.13B$8.52B$13.86B0.27x

Balance Sheet Snapshot 2025

Total Assets$86.71B
Total Liabilities$33.94B
Equity$52.13B
Retained Earnings$49.78B
Goodwill$24.04B
Long-Term Debt$9.90B

Cash Flow Statement

2021 – 2025, Annual

Operating · Investing · Financing

Operating — cash from core business.Investing — buying/selling long-term assets.Financing — debt, equity & dividends.

Free Cash Flow

Operating cash flow minus capital expenditure — the cash available after maintaining operations.

PeriodOperatingInvestingFinancingFCFCapEx
2021$0$0$0$0$0
2022$10B$-2B$-8B$8B$-2B
2023$7B$-3B$-7B$5B$-2B
2024$9B$-2B$-5B$6B$-2B
2025$10B$-2B$-6B$7B$-2B

Capital Allocation 2025

CapEx$2.17B
Dividends Paid$4.12B
Buybacks$893.0M
Debt Repaid$1.50B
Debt Issued$5.0M
Net Change Cash$835.0M

Price History

Chart Terminal →Technical Analysis →

Company Profile

Sector
Healthcare
Industry
Medical Devices
Employees
122,000
HQ
Abbott Park, IL, United States
Web
abbott.com

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company offers pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices. The company was formerly known as Abbott Alkaloidal Company and changed its name to Abbott Laboratories in 1915. Abbott Laboratories was founded in 1888 and is based in Abbott Park, Illinois.

Top Executives

NameTitleTotal Pay
Mr. Robert B. FordExecutive Chairman & CEO$4.4M
Mr. Philip P. BoudreauCFO & Executive VP of Finance$2.1M
Mr. Daniel Gesua Sive SalvadoriExecutive VP and Group President of Established Pharmaceuticals & Nutritional Products$1.5M
Mr. Christopher J. ScogginsExecutive Vice President of Diabetes Care$2.1M
Ms. Lisa D. EarnhardtExecutive VP & Group President of Medical Devices$2.4M
Ms. Sabina EwingSenior VP of Business & Technology Services and Chief Information Officer—
Mr. Michael ComillaVice President of Investor Relations.—
Erica L. BattagliaVP and Chief Ethics & Compliance Officer—
Ms. Elizabeth C. CushmanExecutive VP, General Counsel & Secretary—
Ms. Melissa BrotzSenior Vice President of Global Marketing & External Affairs—

Price Ranges

52-Week
$81.97$137.49
Fwd P/E18.1
Avg Volume12.5M
Shares Out1.73B

Key Ratios

Gross Margin56.8%
Operating Margin14.7%
Profit Margin11.6%
ROE10.6%
ROA5.3%
P/B3.7
D/E63.21
Current Ratio1.38
Dividend Rate$2.52
Payout Ratio79.0%

Cash & Debt

Cash 15%Debt 85%
Total Cash$5.60B
Total Debt$32.72B
Net Cash$-27.12B
Free Cash Flow$7.21B
Operating CF$9.91B

Ratings Snapshot

2.5 / 5
P/E2/5(35.6)
P/B3/5(3.7)
ROE3/5(10.6)
ROA3/5(5.3)
D/E1/5(63.2)
Liquidity3/5(1.4)

Growth Pulse

Revenue Growth+13.0%
Earnings Growth-47.5%

Analyst Recommendations

0m
Buy (27 analysts)
4
16
7
Strong Buy: 4
Buy: 16
Hold: 7
Sell: 0
Strong Sell: 0
MonthStr BuyBuyHoldSellStr Sell
0m416700
-1m416700
-2m417700
-3m416700

Financial Statements

✓
Profitable
4/5 periods
✓
Revenue Growing
+5.7% latest, 2/3 up
✗
Earnings Growing
-51.3% latest, 1/3 up
✗
Pays Dividend
No dividends
✓
Positive Margin
11.6% net margin

Abbott Laboratories

Healthcare \u00b7 Medical Devices

Market Cap$189.86B
Trailing P/E35.6
Forward P/E18.1
EPS (trailing)$3.08
EPS (forward)$6.06
Gross Margin56.8%
Operating Margin14.7%
Profit Margin11.6%
Dividend Rate$2.52/share
Dividend Yield232.0%
Payout Ratio79.0%

Revenue & Net Income

2021 – 2025, Annual

Revenue

Net Income

Profit Margins

2021 – 2025, Annual

Earnings Per Share

2021 – 2025, Annual

Dividends

No dividend history available.

Income Snapshot 2025

Revenue
$44.3B
Net Income
$6.5B
Gross Margin
56.4%
Net Margin
14.7%
Op. Income
$8.1B
EPS
$3.76

Balance Sheet

2021 – 2025, Annual
Debt / Equity0.27x
Owns more than it owes — healthy
Current Ratio1.58x
Can easily cover short-term bills
Net Debt$5.34B
Total debt minus cash on hand

Assets vs Liabilities vs Equity

Assets = Liabilities + Equity. The green bar is what's left for shareholders after paying all debts.

Cash vs Debt

How much cash the company has on hand vs how much it owes in total debt.

Period Detail

PeriodAssetsLiabilitiesEquityCashDebtD/E
2021N/AN/AN/AN/AN/A—
2022$74.44B$37.53B$36.69B$9.88B$17.72B0.48x
2023$73.21B$34.39B$38.60B$6.90B$15.63B0.40x
2024$81.41B$33.51B$47.66B$7.62B$15.02B0.32x
2025$86.71B$33.94B$52.13B$8.52B$13.86B0.27x

Balance Sheet Snapshot 2025

Total Assets$86.71B
Total Liabilities$33.94B
Equity$52.13B
Retained Earnings$49.78B
Goodwill$24.04B
Long-Term Debt$9.90B

Cash Flow Statement

2021 – 2025, Annual

Operating · Investing · Financing

Operating — cash from core business.Investing — buying/selling long-term assets.Financing — debt, equity & dividends.

Free Cash Flow

Operating cash flow minus capital expenditure — the cash available after maintaining operations.

PeriodOperatingInvestingFinancingFCFCapEx
2021$0$0$0$0$0
2022$10B$-2B$-8B$8B$-2B
2023$7B$-3B$-7B$5B$-2B
2024$9B$-2B$-5B$6B$-2B
2025$10B$-2B$-6B$7B$-2B

Capital Allocation 2025

CapEx$2.17B
Dividends Paid$4.12B
Buybacks$893.0M
Debt Repaid$1.50B
Debt Issued$5.0M
Net Change Cash$835.0M
0∑×

Free market data & analysis tools.

Markets
HomeScreenerHeatmapSectorsEarnings
Tools
WatchlistCompareChart TerminalTechnical
Research
CongressInsidersDividendsCorrelation
© 2026 ShounyaAlpha v0.1.0Not financial advice · hanabira.org